MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
sale of common stock...
$2,313K
Sales and maturities
of marketable...
$6,000K
Net proceeds from
sale of common stock...
$70K
Net proceeds from
option exercises
$7K
Net cash provided by
financing activities
$2,112K
Net cash used in
investing activities
$104K
Canceled cashflow
$278K
Canceled cashflow
$5,896K
Net change in cash
and cash...
-$15,415K
Canceled cashflow
$2,216K
Stock-based compensation
$1,096K
Accounts payable and
accrued expenses
$294K
Prepaid expenses and
other current assets
-$284K
Amortization of operating
lease right-of-use...
$135K
Depreciation and
amortization
$54K
Repayment of notes payable
$278K
Purchases of marketable
securities
$5,870K
Purchases of laboratory
and other equipment
$26K
Net cash used in
operating activities
-$17,631K
Canceled cashflow
$1,863K
Net loss
-$18,899K
Deferred revenue, net of
deferred contract...
-$284K
Operating lease liability
-$159K
Accretion on marketable
securities
-$142K
Other assets
$9K
Non-cash interest
expense
-$1K
Back
Back
Cash Flow
source: myfinsight.com
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)